产品
编 号：F324537
分子式：C15H18O8
分子量：326.3
分子式：C15H18O8
分子量：326.3
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
184
In-stock
10mg
296
In-stock
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 33570-04-6
产品详情
生物活性：
Bilobalide, a sesquiterpene trilactone constituent of Ginkgo biloba, inhibits the NMDA-induced efflux of choline with an IC50 value of 2.3 μM. Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells. Exerts protective and trophic effects on neurons.
体内研究：
Bilobalide (20 mg/kg) completely suppresses the NMDA-induced release of choline in vivo while basal choline levels were not significantly affected. NMDA causes a release of choline in vivo when infused into the hippocampus of freely moving rats by retrograde dialysis. Bilobalide (20 mg/kg i.p.) completely inhibits the effect induced by NMDA.Animal Model:Male Wistar rats (250-350 g)
Dosage:20 mg/kg
Administration:I.p. injection 60 min before NMDA infusion
Result:Lowered basal choline efflux only slightly (by 7%) but fully antagonized the NMDA-induced increase of choline release. The convulsive effect of NMDA was almost completely suppressed.
体外研究：
Bilobalide (1-100 μM) completely suppresses the NMDA-evoked release of choline in a concentration-dependent manner with IC50 value of 2.3 μM.Bilobalide (1, 5 and 10 μM) alone for 24 h does not affect cell viability of SH-SY5Y cells. Pre-treatment of cells with Bilobalide concentration-dependently prevents Aβ 1-42-, H2O2- and serum deprivation-induced decrease of cell viability, with the best protective effect obtained at 10 μM. Bilobalide (5 and 10 μM; 24 h) treatment dose-dependently increases levels of p-Akt (Ser473 and Thr308) in SH-SY5Y cells.
Bilobalide, a sesquiterpene trilactone constituent of Ginkgo biloba, inhibits the NMDA-induced efflux of choline with an IC50 value of 2.3 μM. Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells. Exerts protective and trophic effects on neurons.
体内研究：
Bilobalide (20 mg/kg) completely suppresses the NMDA-induced release of choline in vivo while basal choline levels were not significantly affected. NMDA causes a release of choline in vivo when infused into the hippocampus of freely moving rats by retrograde dialysis. Bilobalide (20 mg/kg i.p.) completely inhibits the effect induced by NMDA.Animal Model:Male Wistar rats (250-350 g)
Dosage:20 mg/kg
Administration:I.p. injection 60 min before NMDA infusion
Result:Lowered basal choline efflux only slightly (by 7%) but fully antagonized the NMDA-induced increase of choline release. The convulsive effect of NMDA was almost completely suppressed.
体外研究：
Bilobalide (1-100 μM) completely suppresses the NMDA-evoked release of choline in a concentration-dependent manner with IC50 value of 2.3 μM.Bilobalide (1, 5 and 10 μM) alone for 24 h does not affect cell viability of SH-SY5Y cells. Pre-treatment of cells with Bilobalide concentration-dependently prevents Aβ 1-42-, H2O2- and serum deprivation-induced decrease of cell viability, with the best protective effect obtained at 10 μM. Bilobalide (5 and 10 μM; 24 h) treatment dose-dependently increases levels of p-Akt (Ser473 and Thr308) in SH-SY5Y cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备